Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c
August 5, 2021 7:58 AM EDTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.41), $0.11 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.84 million versus the consensus estimate of $9.54 million.
The second quarter was extremely busy and very successful, highlighted by the proposed acquisition of Strongbridge Biopharma. We continued to see strong demand for Gvoke, driven by HypoPen sales, as evidenced... More
